The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of January 2021. This month is one evidence summary that impacts upon primary care.
The Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections evidence summary has been published. The likely place in therapy for delafloxacin is as an option for adults needing hospital treatment for severe acute bacterial skin and skin structure infections (ABSSSI), primarily cellulitis or erysipelas, abscesses and wound infections, when standard oral and intravenous treatments are not suitable. Intravenous treatment may be switched to oral treatment after 3 days if possible. It would be expected that any necessary completion of treatment is provided on discharge.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.